Envista Stock Price, News & Analysis (NYSE:NVST)

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Envista in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NVST shares.
View NVST analyst ratings or view top-rated stocks.

7 brokers have issued 1 year target prices for Envista's shares. Their NVST share price targets range from $25.00 to $45.00. On average, they predict the company's stock price to reach $34.63 in the next year. This suggests a possible upside of 46.1% from the stock's current price.
View analysts price targets for NVST or view top-rated stocks among Wall Street analysts.

Envista's stock was trading at $33.67 at the start of the year. Since then, NVST stock has decreased by 29.6% and is now trading at $23.70.
View the best growth stocks for 2023 here.

Envista saw a increase in short interest in the month of October. As of October 31st, there was short interest totaling 7,630,000 shares, an increase of 30.7% from the October 15th total of 5,840,000 shares. Based on an average daily trading volume, of 2,180,000 shares, the days-to-cover ratio is presently 3.5 days.
View Envista's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 14th 2024.
View our NVST earnings forecast.

Envista Holdings Co. (NYSE:NVST) issued its earnings results on Wednesday, November, 1st. The company reported $0.43 EPS for the quarter, missing the consensus estimate of $0.46 by $0.03. The firm earned $631.30 million during the quarter, compared to analyst estimates of $647.94 million. Envista had a trailing twelve-month return on equity of 7.29% and a net margin of 7.39%. The firm's quarterly revenue was up .0% on a year-over-year basis. During the same quarter last year, the company earned $0.47 EPS.

ETFs with the largest weight of Envista (NYSE:NVST) stock in their portfolio include Thrivent Small-Mid Cap ESG ETF (TSME), First Trust Health Care AlphaDEX Fund (FXH), Schwab Ariel ESG ETF (SAEF), SPDR S&P Health Care Equipment ETF (XHE), SPDR S&P 400 Mid Cap Value ETF (MDYV), Vanguard S&P Mid-Cap 400 Value ETF (IVOV), iShares U.S. Medical Devices ETF (IHI) and iShares S&P Mid-Cap 400 Value ETF (IJJ).

9 employees have rated Envista Chief Executive Officer Amir Aghdaei on Glassdoor.com. Amir Aghdaei has an approval rating of 21% among the company's employees. This puts Amir Aghdaei in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

(NVST) raised $603 million in an IPO on Wednesday, September 18th 2019. The company issued 26,800,000 shares at a price of $21.00-$24.00 per share. J.P. Morgan, Goldman Sachs and Morgan Stanley acted as the underwriters for the IPO and Baird, Evercore ISI, Jefferies, BofA Merrill Lynch, Credit Suisse, Stifel and William Blair were co-managers.

Envista's stock is owned by many different institutional and retail investors. Top institutional investors include Lazard Asset Management LLC (4.41%), Massachusetts Financial Services Co. MA (4.04%), Gates Capital Management Inc. (3.30%), Ariel Investments LLC (3.11%), Charles Schwab Investment Management Inc. (1.13%) and Montrusco Bolton Investments Inc. (1.11%). Insiders that own company stock include Amir Aghdaei, Curt W Bludworth, Curt W Bludworth, Eric Conley, Howard H Yu, Jeffrey Kappler, Mark E Nance, Mark E Nance, Mischa Reis and Stephen Keller.
View institutional ownership trends.

Shares of NVST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.